{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:52:15Z","timestamp":1792569135387,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["8056-00010A"],"award-info":[{"award-number":["8056-00010A"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF220C0080684"],"award-info":[{"award-number":["NNF220C0080684"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002808","name":"Carlsbergfondet","doi-asserted-by":"publisher","award":["CF21-0363"],"award-info":[{"award-number":["CF21-0363"]}],"id":[{"id":"10.13039\/501100002808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CA 311\/4-1 & FANEDIT\/EJPRD20-209"],"award-info":[{"award-number":["CA 311\/4-1 & FANEDIT\/EJPRD20-209"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chronic granulomatous disease (CGD) is a severe inborn error of immunity caused by NADPH oxidase defects. Here, we develop CRISPR\/Cas9-based gene editing strategies for correction of variants in the\n                    <jats:italic>CYBA<\/jats:italic>\n                    and\n                    <jats:italic>CYBB<\/jats:italic>\n                    genes causing CGD. For X-linked CGD, we also develop a near-universal gene editing strategy by targeted integration of a truncated\n                    <jats:italic>CYBB<\/jats:italic>\n                    cDNA in CD34\n                    <jats:sup>+<\/jats:sup>\n                    hematopoietic stem and progenitor cells (HSPCs). Throughout, off-target editing and chromosomal translocations are evident, which negatively impact the ability of gene-edited HSPCs to engraft in immunodeficient mice. However, by employing a high-fidelity Cas9 to minimize off-target editing, we demonstrate restoration of the multilineage engraftment potential of gene-edited HSPCs. Moreover, to further improve safety, we develop a D10A Cas9n editing approach with no detectable off-target activity or chromosomal translocations. Collectively, through risk assessments of different gene editing approaches, we present a D10A Cas9n-based strategy with improved safety, offering a potentially curative treatment for CGD patients.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-62738-2","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:37:46Z","timestamp":1755013066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeted gene editing and near-universal cDNA insertion of CYBA and CYBB as a treatment for chronic granulomatous disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5690-7603","authenticated-orcid":false,"given":"Jonas Holst","family":"Wolff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Wisbech","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-5814","authenticated-orcid":false,"given":"Didde","family":"Haslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie Rahbek","family":"Dorset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Louise S.","family":"Revenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Aussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie E.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-7531","authenticated-orcid":false,"given":"Martin K.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-1890","authenticated-orcid":false,"given":"Sandra","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-4630","authenticated-orcid":false,"given":"Toni","family":"Cathomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-9704","authenticated-orcid":false,"given":"Trine H.","family":"Mogensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne Kuno","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-0297","authenticated-orcid":false,"given":"Rasmus O.","family":"Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1322-3209","authenticated-orcid":false,"given":"Jacob Giehm","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"62738_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00005792-200005000-00003","volume":"79","author":"JA Winkelstein","year":"2000","unstructured":"Winkelstein, J. A. et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine 79, 155\u2013169 (2000).","journal-title":"Medicine"},{"key":"62738_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12016-020-08800-x","volume":"61","author":"H-H Yu","year":"2021","unstructured":"Yu, H.-H., Yang, Y.-H. & Chiang, B.-L. Chronic granulomatous disease: a comprehensive review. Clin. Rev. Allergy Immunol. 61, 101\u2013113 (2021).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"62738_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/00005792-200005000-00004","volume":"79","author":"BH Segal","year":"2000","unstructured":"Segal, B. H., Leto, T. L., Gallin, J. I., Malech, H. L. & Holland, S. M. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine 79, 170\u2013200 (2000).","journal-title":"Medicine"},{"key":"62738_CR4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood.2020005590","volume":"136","author":"R Chiesa","year":"2020","unstructured":"Chiesa, R. et al. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood 136, 1201\u20131211 (2020).","journal-title":"Blood"},{"key":"62738_CR5","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1089\/ars.2008.2114","volume":"10","author":"K Naka","year":"2008","unstructured":"Naka, K., Muraguchi, T., Hoshii, T. & Hirao, A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid. Redox Signal 10, 1883\u20131894 (2008).","journal-title":"Antioxid. Redox Signal"},{"key":"62738_CR6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","volume":"539","author":"DP Dever","year":"2016","unstructured":"Dever, D. P. et al. CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells. Nature 539, 384\u2013389 (2016).","journal-title":"Nature"},{"key":"62738_CR7","doi-asserted-by":"publisher","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","volume":"8","author":"MA DeWitt","year":"2016","unstructured":"DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).","journal-title":"Sci. Transl. Med."},{"key":"62738_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nprot.2017.143","volume":"13","author":"RO Bak","year":"2018","unstructured":"Bak, R. O., Dever, D. P. & Porteus, M. H. CRISPR\/Cas9 genome editing in human hematopoietic stem cells. Nat. Protoc. 13, 358\u2013376 (2018).","journal-title":"Nat. Protoc."},{"key":"62738_CR9","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood-2015-11-683235","volume":"127","author":"N Hubbard","year":"2016","unstructured":"Hubbard, N. et al. Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome. Blood 127, 2513\u20132522 (2016).","journal-title":"Blood"},{"key":"62738_CR10","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1182\/blood.2020008503","volume":"137","author":"SS De Ravin","year":"2021","unstructured":"De Ravin, S. S. et al. Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem\/progenitor cells. Blood 137, 2598\u20132608 (2021).","journal-title":"Blood"},{"key":"62738_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816 (2012).","journal-title":"Science"},{"key":"62738_CR12","doi-asserted-by":"publisher","first-page":"e00471","DOI":"10.7554\/eLife.00471","volume":"2","author":"M Jinek","year":"2013","unstructured":"Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013).","journal-title":"eLife"},{"key":"62738_CR13","doi-asserted-by":"publisher","first-page":"eaah3480","DOI":"10.1126\/scitranslmed.aah3480","volume":"9","author":"SS De Ravin","year":"2017","unstructured":"De Ravin, S. S. et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci. Transl. Med. 9, eaah3480 (2017).","journal-title":"Sci. Transl. Med."},{"key":"62738_CR14","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/j.celrep.2018.04.103","volume":"23","author":"CY Kuo","year":"2018","unstructured":"Kuo, C. Y. et al. Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome. Cell Rep. 23, 2606\u20132616 (2018).","journal-title":"Cell Rep."},{"key":"62738_CR15","doi-asserted-by":"publisher","first-page":"e13545","DOI":"10.15252\/emmm.202013545","volume":"13","author":"V Vavassori","year":"2021","unstructured":"Vavassori, V. et al. Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome. EMBO Mol. Med. 13, e13545 (2021).","journal-title":"EMBO Mol. Med."},{"key":"62738_CR16","doi-asserted-by":"publisher","first-page":"eaan0820","DOI":"10.1126\/scitranslmed.aan0820","volume":"9","author":"G Schiroli","year":"2017","unstructured":"Schiroli, G. et al. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Sci. Transl. Med. 9, eaan0820 (2017).","journal-title":"Sci. Transl. Med."},{"key":"62738_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09614-y","volume":"10","author":"M Pavel-Dinu","year":"2019","unstructured":"Pavel-Dinu, M. et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat. Commun. 10, 1634 (2019).","journal-title":"Nat. Commun."},{"key":"62738_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17626-2","volume":"11","author":"R Rai","year":"2020","unstructured":"Rai, R. et al. Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott-Aldrich Syndrome. Nat. Commun. 11, 4034 (2020).","journal-title":"Nat. Commun."},{"key":"62738_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41591-021-01284-y","volume":"27","author":"MK Cromer","year":"2021","unstructured":"Cromer, M. K. et al. Gene replacement of \u03b1-globin with \u03b2-globin restores hemoglobin balance in \u03b2-thalassemia-derived hematopoietic stem and progenitor cells. Nat. Med. 27, 677\u2013687 (2021).","journal-title":"Nat. Med."},{"key":"62738_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/bloodadvances.2020001996","volume":"5","author":"G Pavani","year":"2021","unstructured":"Pavani, G. et al. Correction of \u03b2-thalassemia by CRISPR\/Cas9 editing of the \u03b1-globin locus in human hematopoietic stem cells. Blood Adv. 5, 1137\u20131153 (2021).","journal-title":"Blood Adv."},{"key":"62738_CR21","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/mt.2016.148","volume":"24","author":"MD Hoban","year":"2016","unstructured":"Hoban, M. D. et al. CRISPR\/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol. Ther. 24, 1561\u20131569 (2016).","journal-title":"Mol. Ther."},{"key":"62738_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40348-018-0086-1","volume":"5","author":"JS Antony","year":"2018","unstructured":"Antony, J. S. et al. Gene correction of HBB mutations in CD34(+) hematopoietic stem cells using Cas9 mRNA and ssODN donors. Mol. Cell Pediatr. 5, 9 (2018).","journal-title":"Mol. Cell Pediatr."},{"key":"62738_CR23","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas, C. A. et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med. 24, 1216\u20131224 (2018).","journal-title":"Nat. Med."},{"key":"62738_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.stem.2019.04.001","volume":"24","author":"RM Martin","year":"2019","unstructured":"Martin, R. M. et al. Highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR-Cas9 RNP and AAV6 donor-mediated homologous recombination. Cell Stem Cell 24, 821\u2013828 e825 (2019).","journal-title":"Cell Stem Cell"},{"key":"62738_CR25","doi-asserted-by":"publisher","first-page":"7955","DOI":"10.1093\/nar\/gkz475","volume":"47","author":"SH Park","year":"2019","unstructured":"Park, S. H. et al. Highly efficient editing of the beta-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. Nucleic Acids Res. 47, 7955\u20137972 (2019).","journal-title":"Nucleic Acids Res."},{"key":"62738_CR26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ymthe.2019.05.014","volume":"27","author":"Z Romero","year":"2019","unstructured":"Romero, Z. et al. Editing the sickle cell disease mutation in human hematopoietic stem cells: comparison of endonucleases and homologous donor templates. Mol. Ther. 27, 1389\u20131406 (2019).","journal-title":"Mol. Ther."},{"key":"62738_CR27","doi-asserted-by":"publisher","first-page":"eabf2444","DOI":"10.1126\/scitranslmed.abf2444","volume":"13","author":"A Lattanzi","year":"2021","unstructured":"Lattanzi, A. et al. Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci. Transl. Med. 13, eabf2444 (2021).","journal-title":"Sci. Transl. Med."},{"key":"62738_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20909-x","volume":"12","author":"AC Wilkinson","year":"2021","unstructured":"Wilkinson, A. C. et al. Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nat. Commun. 12, 686 (2021).","journal-title":"Nat. Commun."},{"key":"62738_CR29","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1093\/nar\/gku402","volume":"42","author":"Y Lin","year":"2014","unstructured":"Lin, Y. et al. CRISPR\/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic acids Res. 42, 7473\u20137485 (2014).","journal-title":"Nucleic acids Res."},{"key":"62738_CR30","doi-asserted-by":"publisher","first-page":"9584","DOI":"10.1093\/nar\/gkt714","volume":"41","author":"TJ Cradick","year":"2013","unstructured":"Cradick, T. J., Fine, E. J., Antico, C. J. & Bao, G. CRISPR\/Cas9 systems targeting \u03b2-globin and CCR5 genes have substantial off-target activity. Nucleic acids Res. 41, 9584\u20139592 (2013).","journal-title":"Nucleic acids Res."},{"key":"62738_CR31","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822\u2013826 (2013).","journal-title":"Nat. Biotechnol."},{"key":"62738_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","volume":"24","author":"G Schiroli","year":"2019","unstructured":"Schiroli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell 24, 551\u2013565.e558 (2019).","journal-title":"Cell Stem Cell"},{"key":"62738_CR33","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41587-020-0551-y","volume":"38","author":"S Ferrari","year":"2020","unstructured":"Ferrari, S. et al. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat. Biotechnol. 38, 1298\u20131308 (2020).","journal-title":"Nat. Biotechnol."},{"key":"62738_CR34","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.stem.2022.09.001","volume":"29","author":"S Ferrari","year":"2022","unstructured":"Ferrari, S. et al. Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. Cell Stem Cell 29, 1428\u20131444.e1429 (2022).","journal-title":"Cell Stem Cell"},{"key":"62738_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature13420","volume":"510","author":"P Genovese","year":"2014","unstructured":"Genovese, P. et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510, 235\u2013240 (2014).","journal-title":"Nature"},{"key":"62738_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49353-3","volume":"15","author":"A Moiani","year":"2024","unstructured":"Moiani, A. et al. Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells. Nat. Commun. 15, 4965 (2024).","journal-title":"Nat. Commun."},{"key":"62738_CR37","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR\u2013Cas9 genome editing induces a p53-mediated DNA damage response. Nat. Med. 24, 927\u2013930 (2018).","journal-title":"Nat. Med."},{"key":"62738_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nbt.4021","volume":"36","author":"MD Canny","year":"2018","unstructured":"Canny, M. D. et al. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. Nat. Biotechnol. 36, 95\u2013102 (2018).","journal-title":"Nat. Biotechnol."},{"key":"62738_CR39","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.stem.2018.10.008","volume":"23","author":"C Petrillo","year":"2018","unstructured":"Petrillo, C. et al. Cyclosporine H overcomes innate immune restrictions to improve lentiviral transduction and gene editing in human hematopoietic stem cells. Cell Stem Cell 23, 820\u2013832. e829 (2018).","journal-title":"Cell Stem Cell"},{"key":"62738_CR40","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1056\/NEJMoa1007097","volume":"363","author":"DB Kuhns","year":"2010","unstructured":"Kuhns, D. B. et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N. Engl. J. Med. 363, 2600\u20132610 (2010).","journal-title":"N. Engl. J. Med."},{"key":"62738_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2021.102587","volume":"90","author":"D Roos","year":"2021","unstructured":"Roos, D. et al. Hematologically important mutations: X-linked chronic granulomatous disease (fourth update). Blood Cells Mol. Dis. 90, 102587 (2021).","journal-title":"Blood Cells Mol. Dis."},{"key":"62738_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm9106","volume":"8","author":"NT Tran","year":"2022","unstructured":"Tran, N. T. et al. Precise CRISPR-Cas\u2013mediated gene repair with minimal off-target and unintended on-target mutations in human hematopoietic stem cells. Sci. Adv. 8, eabm9106 (2022).","journal-title":"Sci. Adv."},{"key":"62738_CR43","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.ymthe.2024.03.006","volume":"32","author":"J Klermund","year":"2024","unstructured":"Klermund, J. et al. On- and off-target effects of paired CRISPR-Cas nickase in primary human cells. Mol. Ther. 32, 1298\u20131310 (2024).","journal-title":"Mol. Ther."},{"key":"62738_CR44","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nbt.2675","volume":"31","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833\u2013838 (2013).","journal-title":"Nat. Biotechnol."},{"key":"62738_CR45","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","volume":"154","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380\u20131389 (2013).","journal-title":"Cell"},{"key":"62738_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98965-y","volume":"11","author":"MS Schubert","year":"2021","unstructured":"Schubert, M. S. et al. Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair. Sci. Rep. 11, 19482 (2021).","journal-title":"Sci. Rep."},{"key":"62738_CR47","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nmeth.2857","volume":"11","author":"B Shen","year":"2014","unstructured":"Shen, B. et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat. Methods 11, 399\u2013402 (2014).","journal-title":"Nat. Methods"},{"key":"62738_CR48","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","volume":"28","author":"G Turchiano","year":"2021","unstructured":"Turchiano, G. et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell 28, 1136\u20131147.e1135 (2021).","journal-title":"Cell Stem Cell"},{"key":"62738_CR49","doi-asserted-by":"publisher","unstructured":"Suchy, F. P. et al. Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02171-w (2024).","DOI":"10.1038\/s41587-024-02171-w"},{"key":"62738_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102229","volume":"35","author":"KM Siow","year":"2024","unstructured":"Siow, K. M. et al. Targeted knock-in of a NCF1 coding sequence into the endogenous NCF2 locus leads to myeloid phenotypic correction of p47phox-deficient chronic granulomatous disease. Mol. Ther. Nucleic Acids 35, 102229 (2024).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"62738_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.omtm.2023.06.003","volume":"30","author":"SR Dorset","year":"2023","unstructured":"Dorset, S. R. & Bak, R. O. The p53 challenge of hematopoietic stem cell gene editing. Mol. Ther. Methods Clin. Dev. 30, 83\u201389 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"62738_CR52","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/crispr.2021.0128","volume":"5","author":"D Allen","year":"2022","unstructured":"Allen, D. et al. High-throughput imaging of CRISPR- and recombinant adeno-associated virus-induced DNA damage response in human hematopoietic stem and progenitor cells. Crispr j. 5, 80\u201394 (2022).","journal-title":"Crispr j."},{"key":"62738_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42036-5","volume":"14","author":"D Allen","year":"2023","unstructured":"Allen, D. et al. CRISPR-Cas9 engineering of the RAG2 locus via complete coding sequence replacement for therapeutic applications. Nat. Commun. 14, 6771 (2023).","journal-title":"Nat. Commun."},{"key":"62738_CR54","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtn.2022.12.006","volume":"31","author":"O Iancu","year":"2023","unstructured":"Iancu, O. et al. Multiplex HDR for disease and correction modeling of SCID by CRISPR genome editing in human HSPCs. Mol. Ther. Nucleic Acids 31, 105\u2013121 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"62738_CR55","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1182\/blood-2023-188963","volume":"142","author":"DC Shyr","year":"2023","unstructured":"Shyr, D. C. et al. One year follow-up on the first patient treated with Nula-Cel: an autologous CRISPR\/Cas9 gene corrected CD34+ cell product to treat sickle cell disease. Blood 142, 5000\u20135000 (2023).","journal-title":"Blood"},{"key":"62738_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43413-w","volume":"15","author":"R Baik","year":"2024","unstructured":"Baik, R. et al. Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells. Nat. Commun. 15, 111 (2024).","journal-title":"Nat. Commun."},{"key":"62738_CR57","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41587-023-01888-4","volume":"42","author":"S Selvaraj","year":"2024","unstructured":"Selvaraj, S. et al. High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition. Nat. Biotechnol. 42, 731\u2013744 (2024).","journal-title":"Nat. Biotechnol."},{"key":"62738_CR58","doi-asserted-by":"publisher","unstructured":"Cullot, G. et al. Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02488-6 (2024).","DOI":"10.1038\/s41587-024-02488-6"},{"key":"62738_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.modgep.2003.10.004","volume":"4","author":"N Gon\u00e7alves-Mendes","year":"2004","unstructured":"Gon\u00e7alves-Mendes, N., Blanchon, L., Meiniel, A., Dastugue, B. & Sapin, V. Placental expression of SCO-spondin during mouse and human development. Gene Expr. Patterns 4, 309\u2013314 (2004).","journal-title":"Gene Expr. Patterns"},{"key":"62738_CR60","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/mi.2017.74","volume":"11","author":"T Schwerd","year":"2018","unstructured":"Schwerd, T. et al. NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. Mucosal Immunol. 11, 562\u2013574 (2018).","journal-title":"Mucosal Immunol."},{"key":"62738_CR61","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/path.1824","volume":"207","author":"I Szanto","year":"2005","unstructured":"Szanto, I. et al. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease.  J. Pathol.207, 164\u2013176 (2005).","journal-title":"J. Pathol."},{"key":"62738_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.freeradbiomed.2016.10.495","volume":"105","author":"RM Jones","year":"2017","unstructured":"Jones, R. M. & Neish, A. S. Redox signaling mediated by the gut microbiota. Free Radic. Biol. Med. 105, 41\u201347 (2017).","journal-title":"Free Radic. Biol. Med."},{"key":"62738_CR63","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ymthe.2016.11.012","volume":"25","author":"CL Sweeney","year":"2017","unstructured":"Sweeney, C. L. et al. Targeted repair of CYBB in X-CGD iPSCs requires retention of intronic sequences for expression and functional correction. Mol. Ther. 25, 321\u2013330 (2017).","journal-title":"Mol. Ther."},{"key":"62738_CR64","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41434-021-00251-z","volume":"28","author":"CL Sweeney","year":"2021","unstructured":"Sweeney, C. L. et al. Correction of X-CGD patient HSPCs by targeted CYBB cDNA insertion using CRISPR\/Cas9 with 53BP1 inhibition for enhanced homology-directed repair. Gene Ther. 28, 373\u2013390 (2021).","journal-title":"Gene Ther."},{"key":"62738_CR65","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824\u2013844 (2020).","journal-title":"Nat. Biotechnol."},{"key":"62738_CR66","doi-asserted-by":"publisher","unstructured":"Fiumara, M. et al. Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-023-01915-4 (2023).","DOI":"10.1038\/s41587-023-01915-4"},{"key":"62738_CR67","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inf. 42, 377\u2013381 (2009).","journal-title":"J. Biomed. Inf."},{"key":"62738_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inf. 95, 103208 (2019).","journal-title":"J. Biomed. Inf."},{"key":"62738_CR69","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nprot.2011.301","volume":"6","author":"IF Khan","year":"2011","unstructured":"Khan, I. F., Hirata, R. K. & Russell, D. W. AAV-mediated gene targeting methods for human cells. Nat. Protoc. 6, 482\u2013501 (2011).","journal-title":"Nat. Protoc."},{"key":"62738_CR70","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3389\/fmicb.2019.01570","volume":"10","author":"D Dobnik","year":"2019","unstructured":"Dobnik, D. et al. Accurate quantification and characterization of Adeno-associated viral vectors. Front. Microbiol. 10, 1570 (2019).","journal-title":"Front. Microbiol."},{"key":"62738_CR71","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/hgtb.2011.034","volume":"23","author":"C Aurnhammer","year":"2012","unstructured":"Aurnhammer, C. et al. Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods 23, 18\u201328 (2012).","journal-title":"Hum. Gene Ther. Methods"},{"key":"62738_CR72","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-4939-9170-9_7","volume":"1961","author":"LB Ryo","year":"2019","unstructured":"Ryo, L. B., Thomsen, E. A. & Mikkelsen, J. G. Production and validation of lentiviral vectors for CRISPR\/Cas9 delivery. Methods Mol. Biol. 1961, 93\u2013109 (2019).","journal-title":"Methods Mol. Biol."},{"key":"62738_CR73","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.282.5393.1497","volume":"282","author":"F Bunz","year":"1998","unstructured":"Bunz, F. et al. Requirement for p53 and p21 to Sustain G2 Arrest After DNA Damage. Science 282, 1497\u20131501 (1998).","journal-title":"Science"},{"key":"62738_CR74","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224\u2013226 (2019).","journal-title":"Nat. Biotechnol."},{"key":"62738_CR75","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41596-020-0309-5","volume":"15","author":"B Wienert","year":"2020","unstructured":"Wienert, B., Wyman, S. K., Yeh, C. D., Conklin, B. R. & Corn, J. E. CRISPR off-target detection with DISCOVER-seq. Nat. Protoc. 15, 1775\u20131799 (2020).","journal-title":"Nat. Protoc."},{"key":"62738_CR76","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41592-023-01840-z","volume":"20","author":"RS Zou","year":"2023","unstructured":"Zou, R. S. et al. Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+. Nat. Methods 20, 706\u2013713 (2023).","journal-title":"Nat. Methods"},{"key":"62738_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1534-x","volume":"19","author":"F Alkan","year":"2018","unstructured":"Alkan, F., Wenzel, A., Anthon, C., Havgaard, J. H. & Gorodkin, J. CRISPR-Cas9 off-targeting assessment with nucleic acid duplex energy parameters. Genome Biol. 19, 177 (2018).","journal-title":"Genome Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62738-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62738-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62738-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T01:16:30Z","timestamp":1757380590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62738-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62738"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62738-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: J.G.M. is a member of the Scientific Advisory Board of nChroma Bio. R.O.B. is a co-founder of and consultant to UNIKUM Tx and is co-inventor on patent number WO2016164356A1, titled \u201cChemically modified guide RNAs for CRISPR\/Cas-mediated gene regulation\u201d co-filed by The Board Of Trustees Of The Leland Stanford Junior University and Agilent Technologies, Inc. with the following inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, and Joel Myerson. The patent is granted and relates to the use of chemically modified guide RNAs used in the manuscript. R.O.B. reports research funding from Novo Nordisk. None of the companies were involved in the present study. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7475"}}